Statistics from Altmetric.com
We read with interest the study by Jover and colleagues (Gut 2006;55:848–55) on the predictive value of the DNA mismatch repair (MMR) or microsatellite instability (MSI) phenotype for response of colorectal cancer patients to 5-fluorouracil (5-FU) chemotherapy. We are concerned however about the conclusion reached by the authors and the accompanying commentary (Gut 2006;55:759–61) that MSI status should be considered in decisions on the use of 5-FU. While the clinical utility of MSI status for screening of hereditary non-polyposis colorectal cancer (HNPCC) is unquestioned, we are of the opinion that currently available data cannot justify exclusion of patients with MSI tumours from receiving 5-FU treatment.
The authors state that “5-FU based chemotherapy may not be useful in stage II and III MMR deficient colorectal cancer and a revision …
Conflict of interest: None declared.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.